StockNews.com Begins Coverage on Athersys (NASDAQ:ATHX)

Research analysts at StockNews.com started coverage on shares of Athersys (NASDAQ:ATHX) in a note issued to investors on Saturday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

Shares of ATHX stock opened at $0.00 on Friday. Athersys has a fifty-two week low of $0.01 and a fifty-two week high of $1.99. The firm has a market capitalization of $277,735.50, a PE ratio of 0.00 and a beta of -0.90. The stock’s 50-day simple moving average is $0.01 and its 200-day simple moving average is $0.03.

Hedge Funds Weigh In On Athersys

Institutional investors have recently bought and sold shares of the business. Private Advisor Group LLC acquired a new stake in Athersys during the 1st quarter valued at approximately $27,000. BNP Paribas Arbitrage SA raised its holdings in shares of Athersys by 604.4% during the second quarter. BNP Paribas Arbitrage SA now owns 129,530 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 111,140 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in Athersys during the fourth quarter valued at $36,000. CIBC Asset Management Inc purchased a new stake in Athersys in the first quarter valued at $45,000. Finally, Jane Street Group LLC grew its position in Athersys by 438.1% during the 2nd quarter. Jane Street Group LLC now owns 186,076 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 151,494 shares during the period. 19.35% of the stock is owned by hedge funds and other institutional investors.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.